The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Ischemic Heart Disease (IHD) Drugs Market By 2030 Based On Its 2026 Value?
The ischemic heart disease (ihd) drugs market has shown consistent expansion in recent years. It is anticipated to grow from $6.65 billion in 2025 to $6.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.7%. This growth witnessed during past periods can be attributed to the increasing prevalence of coronary artery disease, a rising geriatric population, greater awareness of cardiovascular health, a high incidence of lifestyle-related risk factors, and the availability of generic drugs.
The ischemic heart disease (ihd) drugs market is projected to experience consistent expansion over the coming years. Its valuation is anticipated to reach $7.99 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. This projected increase during the forecast period is largely due to several factors, including breakthroughs in precision medicine, the integration of digital health technologies, a rise in the adoption of combination therapies, the creation of innovative drug delivery systems, and the broadening reach of telehealth and remote monitoring services. Significant developments expected during this period encompass personalized cardiac treatment, new combination drug formulations, cardiac care facilitated by telemedicine, improved cardiovascular risk assessment and tracking, and the use of minimally invasive drug administration methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Which Core Factors Are Supporting The Expansion Of The Ischemic Heart Disease (IHD) Drugs Market?
The increasing occurrence of heart failure is projected to propel the expansion of the ischemic heart disease (IHD) drug market. Heart failure is a chronic medical condition where the heart’s muscle is unable to pump enough blood to satisfy the body’s requirements for blood and oxygen, which can result in tiredness, breathlessness, and difficulty with everyday tasks. Ischemic heart disease (IHD) drugs play a crucial role in the management of heart failure, as these medications can help prevent heart failure by mitigating its risk factors and symptoms. Ischemic Heart Disease (IHD) drugs work by inhibiting the heart’s pacemaker activity and are beneficial for heart failure patients presenting with reduced ejection fractions and elevated resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age suffer from heart failure (HF), and this prevalence is expected to rise to 8.5 million Americans by 2030. Consequently, the escalating incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug market.
How Is The Ischemic Heart Disease (IHD) Drugs Market Structured Across Different Market Segments?
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
What Trends Are Affecting The Growth Of The Ischemic Heart Disease (IHD) Drugs Market?
Companies operating in the ischemic heart disease (IHD) drugs market are concentrating on securing advanced regulatory clearances and broadening drug indications. This strategic focus aims to enhance therapeutic options and expand their market presence. For example, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the European Commission had approved Camzyos (mavacamten). This drug is recognized as the first allosteric, selective cardiac myosin inhibitor specifically for treating symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). Furthermore, during the same year in the U.S., the FDA greenlit a supplemental new drug application, based on Phase 3 VALOR HCM data, which indicated a notable reduction in the eligibility for septal reduction therapy among treated individuals. Consequently, the escalating regulatory activity and label expansions for myosin inhibitors are fueling growth within the IHD drug market.
Who Are The Companies Shaping The Ischemic Heart Disease (IHD) Drugs Market Landscape?
Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC
Access The Complete Ischemic Heart Disease (IHD) Drugs Market Report:
Which Region Stands As The Largest Contributor To The Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Ischemic Heart Disease (IHD) Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
Browse Through More Reports Similar to the Global Ischemic Heart Disease (IHD) Drugs Market 2026, By The Business Research Company
Ischemic Heart Disease Ihd Drugs Market Report 2026
Acute Ischemic Stroke Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model